Author: [email protected]

Release – Lucky Strike Entertainment Appoints Patrick Chung Executive Vice President of Food & Beverage Operations

Posted on by [email protected]

10/14/2026


MIAMI–(BUSINESS WIRE)– Lucky Strike Entertainment (NYSE: LUCK) today announced the appointment of Patrick Chung as Executive Vice President of Food & Beverage Operations. Chung will lead the Company’s food and beverage operations, with a focus on enhancing the guest experience, strengthening execution and driving profitable growth.

“Food and beverage should be a reason guests choose Lucky Strike, not simply something they order once they arrive,” said Thomas Shannon, Founder, Chairman and Chief Executive Officer of Lucky Strike Entertainment. “Patrick brings a compelling combination of hospitality experience, analytical discipline and a passion for understanding what guests want. Our focus is straightforward: deliver food and drinks our guests love, offer great value and execute consistently. Patrick will help us translate that vision into better menus, stronger performance and more reasons for guests to come back.”

Chung brings more than a decade of experience spanning hospitality, food and beverage strategy, revenue optimization and e-commerce. He joins Lucky Strike from MGM Resorts International, where he most recently served as Director of Hospitality Revenue Strategy & Analytics. In that role, he led the food and beverage revenue strategy and analytics team, partnering with operators, property executives and finance teams on planning and performance across more than 450 food and beverage outlets. His responsibilities included menu engineering, pricing strategy, guest research and the implementation of enterprise-wide revenue initiatives.

At Lucky Strike, Chung will work closely with culinary and field leadership to connect guest insights with practical improvements in the food and beverage experience. His priorities will include refining menu offerings, supporting consistent execution and equipping teams with the tools and information needed to deliver strong results.

Previously, Chung held leadership roles in food and beverage corporate strategy, pricing analytics and menu engineering at MGM Resorts, as well as hospitality analytics at Yaamava’ Resort & Casino. His experience includes partnering with operators on demand forecasting, menu development, new concept evaluations and guest analytics. Earlier in his career, he worked in corporate development at Kigo Kitchen and vendor management at Amazon, building experience in pricing analytics, merchandising and commercial strategy.

Chung earned a Bachelor of Science in Economics from the Wharton School of the University of Pennsylvania, with concentrations in Finance and Marketing.

About Lucky Strike Entertainment:

Lucky Strike Entertainment is one of the world’s premier location-based entertainment platforms. With over 360 locations across North America, Lucky Strike Entertainment provides experiential offerings in bowling (Lucky Strike, Bowlero, AMF), amusements, water parks, and family entertainment centers. The company also owns the Professional Bowlers Association, the major league of bowling and a growing media property that boasts millions of fans around the globe. For more information on Lucky Strike Entertainment, please visit IR.LuckyStrikeEnt.com.

Media:
[email protected]Source: Lucky Strike Entertainment Corporation

Release – Tonix Pharmaceuticals Announces Presentations at World Vaccine Congress Europe 2026

Posted on by [email protected]

October 15, 2026 7:00am EDT

BERKELEY HEIGHTS, N.J., Oct. 15, 2026 (GLOBE NEWSWIRE) — Tonix Pharmaceuticals Holding Corp. (Nasdaq: TNXP) (“Tonix” or “the Company”), a fully integrated, commercial-stage biopharmaceutical company, today announced an oral presentation on TNX-801, a live, attenuated, minimally replicative investigational vaccine platform based on horsepox virus to protect against mpox and other infectious diseases, and a working group session led by Tonix, “Vectored Vaccine Platforms: From Design to Improving Efficacy,” at the World Vaccine Congress Europe held in Amsterdam, Netherlands on October 19-21, 2026.

TNX-801 Presentation Details
Title: TNX-801 Vaccine Platform Safety and Efficacy
Date & Time: Oct. 21, 2026, 1:15 p.m. CEST
Session Category: Emerging & Infectious Diseases
Presenter: Farooq Nasar, Ph.D., MPH, Director, Virology, Research and Development Center (RDC), Tonix Pharmaceuticals

Other Session Details
Title: Working Group: Vectored Vaccine Platforms: From Design to Improving Efficacy
Date & Time: Oct 20, 2026, 11:30 a.m. CEST
Session Category: Working Groups
Presenters: Sina Bavari, Ph.D., Executive Vice President, Infectious Disease, RDC, Tonix Pharmaceuticals; Gabriella Worwa, DVM, Ph.D., Study Director, RDC, Tonix Pharmaceuticals; Matilu Mwau, Senior Principal Clinical Research Scientist, Professor of Infectious Diseases, Kenya Medical Research Institute (KEMRI)

About TNX-801
TNX-801 (recombinant horsepox virus) is an attenuated, minimally replicative, live virus vaccine platform based on horsepox in pre-clinical development to prevent mpox, smallpox, and other emerging infectious diseases. TNX-801 is expected to enter a Phase 1 study in 2027 pending FDA clearance of an Investigational New Drug Application (IND). TNX-801 is in the pre-IND stages of development.

Tonix Pharmaceuticals Holding Corp.
Tonix Pharmaceuticals* is a fully integrated, commercial-stage biopharmaceutical company focused on central nervous system (CNS) disorders, infectious diseases, and immunology conditions with high unmet medical needs. TONMYA® (cyclobenzaprine HCl sublingual tablets 2.8mg), the Company’s flagship internally conceived and developed medicine, is the first treatment for fibromyalgia in more than 15 years. Tonix’s CNS commercial infrastructure supports its marketed products, including its acute migraine products, Zembrace® SymTouch® (sumatriptan injection 3 mg) and Tosymra® (sumatriptan nasal spray 10 mg). Tonix is extending the science behind TONMYA in Phase 2 clinical studies to evaluate the potential of TNX-102 SL in major depressive disorder and acute stress disorder/acute stress reaction. Tonix is also advancing a pipeline of infectious disease programs, including Phase 2-ready monoclonal antibody TNX-4800 (anti-OspA mAb) for Lyme disease prevention in the U.S., and TNX-801 (horsepox, live virus vaccine), a vaccine in development for the prevention of mpox and smallpox. Within immunology, TNX-1500 (anti-CD40L mAb) is a Phase 2-ready, third-generation CD40 ligand inhibitor for the prevention of kidney transplant rejection. To learn more, visit www.tonixpharma.com.

*Tonix’s product development candidates, including TNX-102 SL for new, unapproved indications, are investigational new drugs or biologics. Their efficacy and safety have not been established and have not been approved for any indication.

Zembrace SymTouch and Tosymra are registered trademarks of Tonix Medicines. TONMYA is a registered trademark of Tonix Pharma Limited. All other marks are property of their respective owners.

Forward Looking Statements
Certain statements in this press release are forward-looking within the meaning of the Private Securities Litigation Reform Act of 1995. These statements may be identified by the use of forward-looking words such as “anticipate,” “believe,” “forecast,” “estimate,” “expect,” and “intend,” among others. There are a number of factors that could cause actual events to differ materially from those indicated by such forward-looking statements. These factors include, but are not limited to, risks related to the failure to successfully launch and commercialize TONMYA® and any of our approved products; risks related to the failure to obtain FDA clearances or approvals and noncompliance with FDA regulations; risks related to the timing and progress of clinical development of our product candidates; our need for additional financing; uncertainties of patent protection and litigation; uncertainties of government or third party payor reimbursement; limited research and development efforts and dependence upon third parties; and substantial competition. As with any pharmaceutical under development, there are significant risks in the development, regulatory approval and commercialization of new products. Tonix does not undertake an obligation to update or revise any forward-looking statement. Investors should read the risk factors set in the Company’s Annual Report on Form 10-K for the year ended December 31, 2025, as filed with the SEC on March 12, 2026, and periodic reports filed with the SEC on or after the date thereof. Tonix does not undertake an obligation to update or revise any forward-looking statement. All of Tonix’s forward-looking statements are expressly qualified by all such risk factors and other cautionary statements. The information set forth herein speaks only as of the date thereof.

Investor Contacts
Deborah Elson
Tonix Pharmaceuticals
[email protected] 
[email protected] 

Release – Tectonic Metals Drills 2.41 g/t Au Over 59.44 Metres, Including 11.82 g/t Au Over 10.67 Metres and 39.96 g/t Au Over 3.05 Metres at Alpha Bowl, Flat Gold Project, Alaska

Posted on by [email protected]

Drilling Reveals Additional Gold-Bearing Hydrothermal Breccia Mineralization Style at Chicken Mountain, Expanding Exploration Potential

VANCOUVER, B.C., October 15, 2026 – Tectonic Metals Inc. (“Tectonic” or the “Company”) (TSX-V: TECT; OTCQX: TETOF) today announced results from 19 drill holes at Chicken Mountain, the most advanced of six kilometre-scale intrusion targets at the Company’s flagship 99,840-acre Flat Gold Project (“Flat”) in southwest Alaska, U.S.

Drilling continues to deliver broad, near-surface gold mineralization with substantial higher-grade intervals at Alpha Bowl and Adit, two priority zones within Chicken Mountain’s mineralized footprint, which extends 3.3 kilometres (“km”) in length and up to 700 metres (“m”) in width, and has been drill-tested to a vertical depth of 300 m.

Today’s results are highlighted by:

  • Alpha Bowl: 2.41 grams per tonne gold (“g/t Au”) over 59.44 m, including 11.82 g/t Au over 10.67 m, which includes 39.96 g/t Au over 3.05 m, within a broader surface-starting interval of 1.86 g/t Au over 80.77 m.
  • Adit Zone: 1.52 g/t Au over 42.67 m, including 27.35 g/t Au over 1.52 m and 3.84 g/t Au over the final 13.72 m of the hole, where higher-grade mineralization remains untested beyond the end of the hole.

The results support the potential for near-surface, bulk-tonnage gold mineralization with higher-grade domains that could be relevant to future starter-pit evaluations. Drilling has also identified gold-bearing hydrothermal brecciation at Adit, adding a potentially important mineralization style and new exploration targets at Chicken Mountain.

Tectonic has completed more than 29,000 m of drilling in 2026 to advance resource delineation and expansion at Chicken Mountain, with drilling planned through the end of October. This release reports approximately 2,650 m from 19 holes (18 reverse-circulation (“RC”) and one diamond-core) at Alpha Bowl and Adit Zone (Figure 1).

In addition to today’s results, upcoming catalysts include: assays for 114 drill holes (approximately 22,000 m), column-leach test results and a maiden mineral resource estimate (“MRE”) targeted for Q1 2027, followed by a Preliminary Economic Assessment (“PEA”) targeted for Q2 2027.

Tony Reda, Co-Founder, President & CEO, commented:

“What continues to excite us is the scale emerging at Chicken Mountain. Alpha Bowl alone spans approximately 820 metres along strike, up to 600 metres in width, and has been drill-tested to a vertical depth of over 300 metres. These are substantial dimensions for an individual gold exploration target, yet Alpha Bowl represents just one part of Chicken Mountain’s broader 3.3-kilometre mineralized system. Together with Adit and other mineralized zones, the results continue to demonstrate the potential for a large-scale gold system with multiple higher-grade centres.

“We have tremendous momentum at Flat: 114 drill holes awaiting assays, drilling planned through the end of October, important column-leach results on the horizon and our maiden Mineral Resource Estimate in Q1 2027, followed by a Preliminary Economic Assessment in Q2 2027. The volume of new geological and metallurgical information still to come represents an exciting opportunity to deepen our understanding of this emerging gold system, refine our exploration and development strategy and potentially unlock further value across the 99,840-acre Flat property.”

Alpha Bowl Highlights

Alpha Bowl, the northern extension of the Chicken Mountain intrusion (see news release dated January 15, 2026)1, encompasses a mineralized footprint approximately 820 m along strike and 600 m wide, with gold intersected to at least 300 m depth. The latest drilling has identified significant higher-grade gold mineralization near surface, supporting Alpha Bowl as a target for future starter-pit evaluation (Figures 3 and 4).

  • New At-Surface Gold Intersection: CMR26-170 returned 2.41 g/t Au over 59.44 m, including 11.82 g/t Au over 10.67 m and 39.96 g/t Au over 3.05 m, within a broader surface-starting interval of 1.86 g/t Au over 80.77 m. The hole ended in mineralization, leaving the intersection open beyond the end of the hole and making it a target for follow-up drilling.
  • Higher-Grade Mineralization Within a Broad Gold-Bearing System: CMR26-170 builds on previous drilling, including CMR25-035, which returned 2.23 g/t Au over 41.15 m (see news release dated September 10, 2025)2. CMR26-170 is located 250 m south of CMR25-035, 100 m southeast of CMD25-009 (0.48 g/t Au over 94.00 m) and 170 m northeast of CMD25-010 (1.03 g/t Au over 10.00 m within 0.37 g/t Au over 56.5 m), the latter two both previously reported in the Company’s January 2026 news release. Together, these intersections demonstrate gold mineralization across multiple drill locations and suggest opportunities to delineate higher-grade domains within Alpha Bowl’s extensive mineralized footprint.
  • Expansion and Delineation Underway: Assays are pending from three holes east of CMR26-170, while ongoing drilling at approximately 100 m spacing is testing the lateral extent, geometry and continuity of mineralization.

The combination of broad surface-starting intersections, locally substantial grades and a large mineralized footprint positions Alpha Bowl as a priority target for delineating higher-grade zones within a potential bulk-tonnage, open-pit gold system. 

Adit Zone Highlights

The Adit Zone is a priority gold-bearing corridor associated with a major structural contact between the medium-grained Chicken Mountain and coarse-grained Alpha Bowl monzonites. Building on the 2025 discovery intersection of 4.05 g/t Au over 30.48 m in CMR25-121 (see news release dated December 22, 2025)3, the 2026 program is delineating mineralization along this contact and toward Alpha Bowl.

Adit Main

New 2026 RC drilling continues to intersect broad, near-surface gold mineralization with locally substantial higher-grade intervals:

  • CMR26-160: 0.90 g/t Au over 73.15 m from surface, including 2.14 g/t Au over 21.34 m and 6.97 g/t Au over 4.57 m.
  • CMR26-161: 0.70 g/t Au over 45.72 m from surface, including 1.14 g/t Au over 16.76 m, plus a separate deeper interval of 0.69 g/t Au over 15.24 m, including 4.95 g/t Au over 1.52 m. Drilled at a steeper angle from the same collar as CMR26-160, this hole helps constrain mineralization geometry.
  • CMR26-162: 1.06 g/t Au over 19.81 m, including 1.71 g/t Au over 10.67 m, followed by a separate interval of 0.64 g/t Au over 33.53 m, extending to the end of the hole.
  • CMR26-163: 1.52 g/t Au over 42.67 m, including 27.35 g/t Au over 1.52 m and 3.84 g/t Au over the final 13.72 m of the hole.
  • CMR26-171: 0.66 g/t Au over 35.05 m, including 1.00 g/t Au over 18.29 m and 1.63 g/t Au over 9.14 m, with mineralization extending to the end of the hole.

These results further support the Chicken Mountain-Alpha Bowl intrusive contact as a priority exploration target, with broad mineralized intervals and localized higher-grade concentrations suggesting structural and lithological controls on gold distribution. Notably, CMR26-162, CMR26-163 and CMR26-171 all ended in mineralization, including CMR26-163, which returned 3.84 g/t Au over its final 13.72 m, leaving the extent of these intersections unresolved (Figures 5 and 6).

The combination of near-surface mineralization, higher-grade internal intervals and multiple drill holes ending in mineralization supports Adit Main as a target for delineating bulk-tonnage gold mineralization with higher-grade domains. Follow-up drilling will establish continuity along the intrusive contact, extend mineralization beyond current drill limits and evaluate the potential for near-surface higher-grade zones that could contribute to future starter-pit evaluation.

Gold-Bearing Breccia Expands Exploration Targets

Diamond hole CMD26-054 intersected 0.73 g/t Au over 43.50 m, including 1.22 g/t Au over 15.00 m, within a multi-stage hydrothermal breccia interpreted to have formed through repeated episodes of faulting, brecciation and veining. The hydrothermal intersection in drill core shows multistage faulting with veins and brecciation and later carbonate and iron staining (see Figures 7 to 11).

Within Chicken Mountain’s interpreted reduced intrusion-related gold system (“RIRGS”), areas where intrusive contacts, faulting and hydrothermal brecciation coincide create additional targeting opportunities. Such sites may have provided localized pathways for gold-bearing fluids and could host mineralized bodies with different geometries from the surrounding sheeted-veinlet arrays.

Tectonic drilled follow-up holes at 100 m spacing to test the breccia’s extent, its relationship to neighbouring mineralization and whether repeated brecciation and veining are associated with gold enrichment. If demonstrated, these relationships could improve targeting of additional mineralized volume and local higher-grade zones along the Adit corridor. Assays are currently pending for CMD26-064 and CMD26-066.

The recognition of this hydrothermal breccia-hosted mineralization is significant because it suggests that mineralizing fluids were active within the system for a prolonged period and capable of multiple mineralizing events. This newly recognized style of mineralization adds an important development to the geologic and mineral model and expands the Company’s exploration potential.

Adit West

The Adit Zone structural contact is interpreted to extend westward along a corridor of coincident soil-geochemical and geophysical anomalies, defining a priority exploration target. Anomalous gold was intersected in seven of eleven holes, and this target remains insufficiently tested. Follow-up drilling from more favourably positioned drill pads will test the continuity and mineralization potential along the Adit West trend.

Drill results for the Adit Zone are shown in Figures 5 and 6.

Near-Term Catalysts

Drilling is expected to continue through the end of the field season in late October, supporting a steady flow of assay results through year-end. The assay pipeline is substantial, with 114 additional drill holes currently in the laboratory queue representing 22,000 m of the 2026 drill program.

Results from the regional soil-sampling program are also pending and will help refine and prioritize exploration targets beyond the current drilled footprint at Flat.

Drilling results and pending column-leach testing will inform the Company’s maiden MRE targeted for Q1 2027, and the PEA targeted for Q2 2027.

Qualified Person   

Tectonic Metals’ disclosure of technical or scientific information in this press release has been reviewed, verified and approved by Peter Kleespies, M.Sc., P.Geo., Chief Geological Officer, who is a Qualified Person in accordance with Canadian regulatory requirements set out in National Instrument 43-101.  

Analytical work for the 2026 Flat project drilling program was performed by ALS Global (“ALS”), an internationally recognized and accredited laboratory independent of Tectonic. On-site, core and reverse circulation samples were sealed in security-tagged bags and shipped under strict chain-of-custody protocols to the Lynden Transport logistics operator in Anchorage, Alaska, for delivery to ALS facilities in Vancouver, British Columbia.

Upon arrival at the laboratory, samples were dried, crushed to 2 mm and riffle split into nominal 500-gram subsample aliquots (prep codes CRU-31, SPL-32a). One portion was analyzed for gold using PhotonAssay™ (ALS code Au-PA01). PhotonAssay™ uses high-energy X-rays to determine gold content from a large sample aliquot, typically 500 g of crushed material. The method is non-destructive and is particularly suited to gold systems where larger sample aliquots may improve representativity. If additional nominal 500-gram PhotonAssayTM analysis splits are conducted for a given sample, results from all splits are combined on a weight average basis. A second portion was pulverized such that 85% of the sample passed 75 µm, (PUL-31) and was analyzed by four-acid digestion with ICP-MS finish for 48 elements (ME-MS61), along with aqua regia digestion with ICP-MS finish for trace levels of mercury (Hg-MS42).

Quality assurance and quality control (QA/QC) protocols included the insertion of certified reference material every 20 samples, blank samples at rate of every 25 samples and field duplicate samples (split from the original 1.5 m for RC or 1.5 m for core intervals) every 25 samples. All QA/QC results returned values within acceptable limits.

About Tectonic Metals Inc.

Tectonic Metals Inc. is a mineral exploration company focused on exploring and developing its flagship Flat Gold Project in southwestern Alaska, covering 99,840 acres of predominantly Native-owned land belonging to Doyon, Ltd., a leading Alaska Native Regional Corporation and one of Tectonic’s largest shareholders. The current focus is on advancing the Chicken Mountain target, one of six multi-kilometre-scale intrusion zones at the Flat Gold Project, towards the Company’s maiden Mineral Resource Estimate in Q1 2027.

Founded by key members of the Kaminak Gold team behind the discovery and advancement of the Coffee Gold Project, which was acquired by Goldcorp for $520 million in 2016, Tectonic brings a proven track record in exploration, project advancement, capital markets and value creation. Collectively, the team has helped identify more than 40 million ounces of gold, advanced 20 projects through to feasibility, permitted 25 projects, completed over $6 billion in mergers and acquisitions and raised more than $6 billion in capital.

Tectonic’s mission is to be a shift in the game: working for our shareholders and the communities where we operate, putting people first, playing big and staying true to our word every step of the way.

On behalf of Tectonic Metals Inc.,  
Tony Reda, President and Chief Executive Officer

For further information about Tectonic Metals Inc. or this news release, please visit our website at www.tectonicmetals.com or contact:

Keren Yun, Vice President, Investor Relations
1-888-685-8558 or [email protected]

Release – Snail Games Subsidiary Interactive Films Launches The Fame Game II: L.A. Heartbreaker, Expanding Its Interactive Hollywood Drama Franchise

Posted on by [email protected]

October 15, 2026 at 8:30 AM EDT

CULVER CITY, Calif., Oct. 15, 2026 (GLOBE NEWSWIRE) — Snail, Inc. (Nasdaq: SNAL) (“Snail Games” or the “Company”), a leading global independent developer and publisher of interactive digital entertainment, today announced the launch of The Fame Game II: L.A. Heartbreaker, the next installment in its interactive entertainment franchise developed and published by its subsidiary Interactive Films LLC.

The Fame Game II: L.A. Heartbreaker builds on the foundation established by The Fame Game: Welcome to Hollywood with a new story centered around identity, ambition, romance, and the high-stakes social world of Los Angeles. Filmed on location throughout Los Angeles by a professional production team with Hollywood film and television experience, the game incorporates feature-film-inspired direction, cinematography, lighting, costume, makeup, and production design to bring its setting to life.

The new installment follows He Shuhan, an ordinary international student who finds himself drawn into Los Angeles’ high society after assuming the identity of a wealthy heir. To maintain the deception, players must navigate five dangerous relationships and make hundreds of choices that shape those relationships, the story’s progression, and potential outcomes. Depending on the decisions made, players may preserve the illusion, lose everything, or uncover relationships that challenge the identity they have created.

Interactive Films expanded audience participation in the development of The Fame Game II: L.A. Heartbreaker through a global casting initiative that drew in more than 200,000 votes that helped shape the game’s cast. The live-action production stars Zhong Chenyao as Ayaka alongside four additional actresses, whose performances bring the game’s central relationships and branching narrative to life.

The expansion of The Fame Game series reflects continued interest in interactive entertainment built around character-driven storytelling and player agency. Relationship-focused games have increasingly moved beyond traditional dating-simulation formats, incorporating cinematic presentation, branching narratives, and community-driven experiences that allow players to engage with stories through their own decisions.

The Fame Game II: L.A. Heartbreaker advances Interactive Films’ combination of accessible interactive fiction and live-action entertainment. The title is designed to encourage replayability as players explore different relationships, choices, and consequences across multiple possible outcomes.

Play The Fame Game II: L.A. Heartbreaker on Steam

For creators interested in covering The Fame Game II: L.A. Heartbreaker, please reach out to [email protected]

The Fame Game II: L.A. Heartbreaker | Press Kit

About Snail, Inc.
Snail, Inc. (Nasdaq: SNAL) is a leading, global independent developer and publisher of interactive digital entertainment for consumers around the world, with a premier portfolio of premium games designed for use on a variety of platforms, including consoles, PCs, and mobile devices. For more information, please visit: https://snail.com/.

About Interactive Films LLC 
Interactive Films (IF), a film and media subsidiary of Snail, Inc., was founded with the goal of reaching new video audiences, engaging enthusiastic viewers, and telling stories across various formats. IF is also the catalyst behind SaltyTV, a specialized film application designed to produce and showcase compelling short-form vertical content. The SaltyTV app is available for download from the iOS App Store and the Google Play Store. For more information, please visit: https://interactive-films.com/.

Forward-Looking Statements
This press release contains statements that constitute forward-looking statements. Many of the forward-looking statements contained in this press release can be identified by the use of forward-looking words such as “anticipate,” “believe,” “could,” “expect,” “should,” “plan,” “intend,” “may,” “predict,” “continue,” “estimate” and “potential,” or the negative of these terms or other similar expressions. These forward-looking statements include information about possible or assumed future results of Snail Games’ business, financial condition, results of operations, liquidity, plans and objectives. Forward-looking statements appear in a number of places in this press release and include, but are not limited to, statements regarding the continued interest in interactive entertainment built around character-driven storytelling and player agency; further developing a format that combines the accessibility of interactive fiction with live-action entertainment; using SaltyTV to produce and showcase compelling short-form vertical content; and assumptions underlying any of the foregoing. Further information on risks, uncertainties and other factors that could affect Snail Games’ financial results and business include Snail Games’ ability to develop new intellectual properties and expand existing franchises through its proprietary development capabilities; Snail Games’ ability to retain its key employees or maintain its Nasdaq listing; and the risks that are included in its filings with the Securities and Exchange Commission (the “SEC”) from time to time, including its annual reports on Form 10-K and quarterly reports on Form 10-Q filed, or to be filed, with the SEC. You should not rely on these forward-looking statements, as actual outcomes and results may differ materially from those expressed or implied in the forward-looking statements as a result of such risks and uncertainties. All forward-looking statements in this press release are based on management’s beliefs and assumptions and on information currently available to Snail Games, and Snail Games does not assume any obligation to update the forward-looking statements provided to reflect events that occur or circumstances that exist after the date on which they were made.

Investor Contact:

John Yi and Steven Shinmachi
Gateway Group, Inc.
949-574-3860
[email protected]

NanoViricides (NNVC) – Ebola Trial Reports Ongoing Enrollment Progress

Posted on by [email protected]

Robert LeBoyer, Senior Vice President, Equity Research Analyst, Biotechnology, Noble Capital Markets, Inc.

Refer to the full report for the price target, fundamental analysis, and rating.

Patient Enrollment and Treatment Continue. Nanoviricides provided an update on the progress of its Phase 2a trial in Ebola, including additional details on its design, endpoints, and objectives. The Phase 2a trial began treating patients with NV-387 in the Democratic Republic of Congo (DRC) in late September. The company reported that enrollment is continuing, with data expected in 1Q27. 

Stages Of Infection Are Emerging. The current outbreak of Ebola virus disease (EVD) in the DRC has been caused by a new variant of the Bundibugyo Ebolavirus (BDBV). The development of symptoms varies between patients, and its diagnosis is still being refined. During the first 5 to 7 days after initial infection, mild symptoms may not even be noticeable. Patients typically seek treatment after about 5 to 7 days, when they begin vomiting and have severe diarrhea. The trial is expected to enroll most patients at this stage.


Get the Full Report

Equity Research is available at no cost to Registered users of Channelchek. Not a Member? Click ‘Join’ to join the Channelchek Community. There is no cost to register, and we never collect credit card information.

This Research is provided by Noble Capital Markets, Inc., a FINRA and S.E.C. registered broker-dealer (B/D).

*Analyst certification and important disclosures included in the full report. NOTE: investment decisions should not be based upon the content of this research summary. Proper due diligence is required before making any investment decision. 

SKYX Platforms (SKYX) – Transformative Acquisition Completed

Posted on by [email protected]


Thursday, October 15, 2026

Joe Gomes, CFA, Managing Director, Equity Research Analyst, Generalist , Noble Capital Markets, Inc.

Refer to the full report for the price target, fundamental analysis, and rating.

Deako. SKYX Platforms has closed the merger with Deako, Inc., which we first covered in our September 11th report. As we noted then, the merger enables SKYX to offer an A-to-Z AI and smart home plug-and-play solution for homes and buildings. The merger significantly expands SKYX’s addressable market and also opens additional avenues of cross-selling opportunities for both companies, in our view.

New Pipeline Details. SKYX noted the combined Company pipeline is over 4 million units with an expected average selling price of approximately $50/product, suggesting a $200 million+ current pipeline. With cross-selling opportunities, SKYX’s full product line is expected to create an opportunity to increase Deako’s revenue per home by up to fivefold; we expect to see strong pipeline growth going forward. And there is the opportunity to cross-sell Deako products into SKYX’s existing projects.


Get the Full Report

Equity Research is available at no cost to Registered users of Channelchek. Not a Member? Click ‘Join’ to join the Channelchek Community. There is no cost to register, and we never collect credit card information.

This Company Sponsored Research is provided by Noble Capital Markets, Inc., a FINRA and S.E.C. registered broker-dealer (B/D).

*Analyst certification and important disclosures included in the full report. NOTE: investment decisions should not be based upon the content of this research summary. Proper due diligence is required before making any investment decision. 

Ocugen (OCGN) – Ocugen Completes Licensing Agreement For MENA Region

Posted on by [email protected]


Thursday, October 15, 2026

Robert LeBoyer, Senior Vice President, Equity Research Analyst, Biotechnology, Noble Capital Markets, Inc.

Refer to the full report for the price target, fundamental analysis, and rating.

Licensing Agreement Finalizes Terms Announced In July. Ocugen and Roots Pharmaceuticals have finalized a licensing agreement for the commercialization of OCU400 in the Middle East and North Africa. The license finalizes the terms that the two companies announced in July 2026. This advances Ocugen’s plan to market OCU400 worldwide.

Collaboration Covers A Large Territory. The agreement gives Kuwait-based Roots Pharmaceuticals and its strategic partner, Al-Dhow International Holding, exclusive rights for the Middle East and North Africa coastal countries (MENA region). Retinitis pigmentosa (RP) is estimated to have a higher incidence in this region than in the US and Europe, although we cannot project sales at this time.


Get the Full Report

Equity Research is available at no cost to Registered users of Channelchek. Not a Member? Click ‘Join’ to join the Channelchek Community. There is no cost to register, and we never collect credit card information.

This Company Sponsored Research is provided by Noble Capital Markets, Inc., a FINRA and S.E.C. registered broker-dealer (B/D).

*Analyst certification and important disclosures included in the full report. NOTE: investment decisions should not be based upon the content of this research summary. Proper due diligence is required before making any investment decision. 

AZZ (AZZ) – Record Results Reinforce Growth Outlook

Posted on by [email protected]


Thursday, October 15, 2026

Mark Reichman, Managing Director, Equity Research Analyst, Natural Resources, Noble Capital Markets, Inc.

Refer to the full report for the price target, fundamental analysis, and rating.

FY 2027 Second Quarter Results Exceed Expectations. AZZ reported adjusted net income of $60.1 million, or $2.00 per diluted share, compared with $46.9 million, or $1.55 per share, in the prior-year period. Results exceeded our estimates of $54.9 million, or $1.81 per share, by 9.5% and 10.5%, respectively. Revenue increased 16.7% to a record $486.9 million, while adjusted EBITDA rose 25.0% to $110.9 million, exceeding our $101.6 million estimate. Adjusted EBITDA margin expanded 150 basis points to 22.8%. Metal Coatings revenue increased 22.9% to $233.5 million, while Precoat Metals revenue rose 11.5% to $253.4 million. Segment adjusted EBITDA margins were 30.7% and 21.2%, respectively.

FY 2027 Corporate Guidance Raised. Reflecting strong first-half results and sustained operating momentum, management increased FY 2027 revenue guidance to $1.825 to $1.875 billion from $1.800 to 1.850 billion. Adjusted EBITDA guidance increased to $380 to $420 million from $375 to $415 million, while adjusted diluted EPS guidance rose to $7.00 to $7.30 from $6.75 to $7.15.


Get the Full Report

Equity Research is available at no cost to Registered users of Channelchek. Not a Member? Click ‘Join’ to join the Channelchek Community. There is no cost to register, and we never collect credit card information.

This Company Sponsored Research is provided by Noble Capital Markets, Inc., a FINRA and S.E.C. registered broker-dealer (B/D).

*Analyst certification and important disclosures included in the full report. NOTE: investment decisions should not be based upon the content of this research summary. Proper due diligence is required before making any investment decision. 

Wholesale Inflation Surges in September, Raising Pressure on Federal Reserve to Consider Another Rate Hike

Posted on by [email protected]

U.S. wholesale prices surged more than expected in September, adding to concerns that inflation remains a significant challenge for the economy and increasing pressure on the Federal Reserve to consider another interest rate hike before the end of the year.

According to data released Thursday, October 15, by the Bureau of Labor Statistics, the Producer Price Index (PPI), which measures prices received by domestic producers for goods and services, increased 1.3% in September following a 0.5% rise in August. The monthly increase was the largest since March 2022 and significantly exceeded economists’ expectations of a 0.5% gain.

On an annual basis, wholesale prices climbed 6.3%, accelerating from 5.6% in August and reaching their highest year-over-year growth rate since December 2022.

The stronger-than-expected report suggests that inflationary pressures remain widespread across the economy, complicating the Federal Reserve’s efforts to bring inflation closer to its 2% target.

Energy prices were a major contributor to September’s increase. Prices for final demand goods rose 2.6%, driven largely by a 10.8% jump in energy costs. Gasoline prices increased 20.3%, while diesel, jet fuel, and electricity prices also moved higher.

Higher energy costs can have significant implications beyond the fuel industry. Businesses across manufacturing, agriculture, transportation, and retail depend on energy to operate, meaning sustained price increases can eventually translate into higher costs for consumers.

Inflationary pressures were also evident in the services sector, where prices increased 0.8% during September. Transportation and warehousing costs continued to rise, reflecting the growing expense of moving goods throughout the economy.

Even excluding the volatile food and energy categories, producer prices increased 0.7% during the month, substantially above expectations. Core wholesale inflation reached 5.0% annually, indicating that price pressures are extending beyond energy markets.

The report follows Wednesday’s release of September consumer inflation data, which also showed accelerating prices. Together, the two reports suggest that inflation may prove more persistent than policymakers had anticipated.

The Federal Reserve now faces a difficult decision ahead of its October 27–28 policy meeting. After raising interest rates in September, policymakers must determine whether additional tightening is necessary to contain inflation without placing excessive pressure on economic growth.

Higher interest rates generally increase borrowing costs for businesses and consumers, potentially slowing spending, investment, and hiring. While these measures can help reduce inflation, they can also create challenges for companies that depend on affordable financing.

Small-cap and microcap businesses may be particularly sensitive to prolonged periods of elevated interest rates. Companies with limited cash reserves, substantial borrowing requirements, or ongoing capital investment needs could face additional financial pressure if borrowing costs remain high.

Rising producer prices can also squeeze corporate profit margins, especially for businesses unable to pass higher operating expenses along to customers.

For investors, the latest inflation figures reinforce the importance of monitoring both monetary policy and company-specific financial performance. Businesses with strong balance sheets, pricing flexibility, and manageable debt obligations may be better positioned to navigate an extended period of higher costs.

With wholesale inflation accelerating and consumer prices continuing to rise, the Federal Reserve’s upcoming decision will be closely watched for signals about the direction of interest rates and the broader economic outlook.

Why Are AI Stocks Falling? Nvidia, CoreWeave Slide as Investors Question the AI Boom

Posted on by [email protected]

Artificial intelligence stocks are facing renewed selling pressure as investors question whether the enormous spending fueling the AI boom can translate into sustainable profits. Shares of Nvidia (NASDAQ: NVDA), CoreWeave (NASDAQ: CRWV), and other AI-linked companies declined Thursday, October 15, as rising borrowing costs and concerns about debt-financed infrastructure investments weighed on technology stocks.

The selloff has spread across the semiconductor and cloud computing industries, raising questions about the sustainability of one of Wall Street’s most closely watched investment trends.

CoreWeave has emerged as a focal point of investor concerns. The AI cloud computing company, which provides access to high-performance Nvidia processors, has relied heavily on borrowing to expand its data center infrastructure and meet growing demand for computing power.

However, the company’s substantial debt obligations have attracted increased scrutiny as interest rates remain elevated. CoreWeave shares fell more than 15% Wednesday and continued declining during Thursday’s trading session, while yields on some of its corporate bonds climbed to distressed levels.

The broader technology sector has also experienced significant losses. Nvidia shares fell approximately 3% during Thursday morning’s trading, while Advanced Micro Devices (NASDAQ: AMD) and Micron Technology (NASDAQ: MU) recorded even steeper declines.

The Philadelphia Semiconductor Index has lost more than $1.6 trillion in market capitalization over six trading sessions, illustrating how quickly investor sentiment toward AI-related investments has shifted.

Much of the concern centers on the extraordinary amount of capital being committed to artificial intelligence infrastructure.

Major technology companies are investing billions of dollars in data centers, advanced processors, networking equipment, and energy infrastructure to support increasingly sophisticated AI models. While demand for AI computing remains substantial, investors are beginning to examine whether future revenue will justify these expenditures.

Higher interest rates have added another layer of uncertainty. Recent inflation reports have increased expectations that the Federal Reserve could raise borrowing costs further, potentially making debt-financed technology projects more expensive.

For companies dependent on external financing, higher interest expenses can reduce profitability and complicate expansion plans.

The situation also highlights a growing distinction between companies supplying AI infrastructure and those financing its development. Semiconductor manufacturers can generate revenue from equipment sales, while data center operators must recover substantial upfront investments through long-term customer contracts.

Despite the market volatility, the AI industry’s underlying growth opportunities have not disappeared. Businesses continue adopting artificial intelligence for automation, data analysis, cybersecurity, and enterprise software, supporting demand for computing infrastructure and specialized technologies.

However, investors are increasingly distinguishing between companies demonstrating sustainable revenue growth and those relying on aggressive spending assumptions.

For small-cap and emerging technology companies, the changing market environment could create both challenges and opportunities. Businesses developing AI applications, semiconductor components, or infrastructure services may benefit from continued adoption, but tighter financing conditions could make raising capital more difficult.

Companies with established customers, recurring revenue, and manageable debt levels may be better positioned to navigate heightened market scrutiny.

The recent selloff does not necessarily signal the end of the AI investment cycle. Instead, it suggests that investors are becoming more selective about how companies finance growth and when their investments are expected to generate meaningful returns.

As artificial intelligence continues reshaping the technology industry, the next phase of the market’s evolution may depend less on spending announcements and more on profitability, cash flow, and financial discipline.

Federal Reserve Faces High-Stakes Interest Rate Decision Days Before Midterm Elections

Posted on by [email protected]

The Federal Reserve is approaching one of its most closely watched interest rate decisions of the year, with policymakers facing renewed inflation concerns just days before the November midterm elections. The central bank’s next policy announcement, scheduled for October 28, comes only six days before Americans head to the polls, creating a politically sensitive environment as officials determine whether additional monetary tightening is necessary.

Fresh inflation data released Wednesday, October 14, has intensified expectations that another rate increase could be on the table. The Consumer Price Index rose 3.7% annually in September, with prices increasing 0.6% from the previous month. Core inflation, which excludes volatile food and energy prices, increased 2.6% year over year and 0.3% monthly, reinforcing concerns that inflationary pressures remain persistent.

The latest figures have complicated the Federal Reserve’s efforts to balance price stability with economic growth. Following the inflation report, financial markets increased the probability of a quarter-percentage-point rate hike at the October meeting to approximately 40%, up from roughly 20% the previous day.

The Federal Reserve already raised its benchmark interest rate in September, marking its first increase in more than three years. That decision brought the federal funds target range to 3.75%–4.00%, signaling policymakers’ determination to address inflation despite concerns about economic momentum.

The upcoming decision presents an additional challenge because of its proximity to the November 3 elections. Interest rate changes can influence borrowing costs, consumer spending, housing affordability, and financial market performance, making monetary policy a closely watched issue during election campaigns.

Historically, the Federal Reserve has often avoided changing interest rates immediately before national elections. An analysis of previous election cycles found that the central bank left rates unchanged approximately 67% of the time between October 1 and Election Day. However, persistent inflation has occasionally prompted policymakers to act despite the political calendar.

Federal Reserve Chairman Kevin Warsh has emphasized the importance of maintaining credibility in the central bank’s efforts to control inflation. The institution faces pressure to demonstrate that its decisions are guided by economic conditions rather than political considerations.

For investors, the implications extend beyond the immediate reaction in stock and bond markets. Higher interest rates can increase financing costs for businesses, discourage borrowing, and place additional pressure on corporate earnings.

These challenges can be particularly significant for small-cap and microcap companies, which often have fewer financing alternatives and greater exposure to changes in credit conditions. Businesses dependent on external capital to support expansion, acquisitions, or research and development may face higher borrowing expenses if monetary policy remains restrictive.

Conversely, a decision to hold rates steady could provide some near-term relief to interest-rate-sensitive sectors, although continued inflation concerns may limit expectations for monetary easing.

Investors will be closely monitoring the Federal Reserve’s October announcement for indications of how policymakers assess inflation risks and the possibility of additional rate increases before year-end.

Whether the central bank raises rates or maintains its current position, the decision will carry implications for financial markets, business investment, and the broader economic outlook.

With inflation proving difficult to contain and political scrutiny intensifying, the Federal Reserve faces a critical test of its commitment to independent, data-driven monetary policy.

Release – Ocugen and Roots Pharmaceutical Complete License Agreement for OCU400 Modifier Gene Therapy for Retinitis Pigmentosa in the Middle East and North Africa

Posted on by [email protected]

October 14, 2026

MALVERN, Pa., Oct. 14, 2026 (GLOBE NEWSWIRE) — Ocugen, Inc. (“Ocugen” or the “Company”) (NASDAQ: OCGN), a pioneering biotechnology leader in gene therapies for blindness diseases, today announced the execution of a licensing agreement with Roots Pharmaceutical, and its strategic partner Al-Dhow International Holding, for the exclusive rights to OCU400, Ocugen’s novel modifier gene therapy for the treatment of Retinitis Pigmentosa (RP), in the Middle East and North Africa (MENA) region.

Subject to the terms of the License Agreement, Ocugen will receive an upfront license fee and potential initial development milestone payments of up to $4 million, in the aggregate, as well as potential sales milestone payments of up to $255 million, and royalties equaling 22% of OCU400 net sales generated by Roots Pharmaceutical. Ocugen will manufacture the commercial supply of OCU400 under terms of a related supply agreement.

Ocugen believes RP is a leading cause of inherited vision loss globally, with a particularly significant unmet need across the MENA region, where the prevalence of RP is estimated to be 10 to 20 times higher than in the U.S. and EU. Through OCU400, Roots Pharmaceutical aims to help address this substantial unmet need by potentially providing a treatment option for people in the MENA region living with RP and facing progressive vision loss and potential blindness.

“By partnering with Roots Pharmaceutical, an established leader with strong reach across the Middle East and North Africa, we are expanding our ability to bring our potential one-time gene therapy to patients in a region where retinitis pigmentosa is highly prevalent and the unmet medical need is significant,” said Dr. Shankar Musunuri, Chairman, Chief Executive Officer and Co-founder of Ocugen. “This agreement represents another important step in our strategy to build strong regional partnerships and expand global access to our potentially transformational gene therapies.”

Roots Pharmaceutical is an established and rapidly growing pharmaceutical company serving key markets across the MENA region. With more than two decades of operating experience and expertise in commercializing innovative medicines, the company’s regional capabilities and established healthcare relationships position it as a strong partner for bringing OCU400 to RP patients across MENA.

“This partnership reflects Roots’ commitment to bringing breakthrough gene therapies to the Middle East and North Africa, leading and shaping the treatment paradigm for our patients, which is our main objective,” said Dr. Islam Zayed, Chief Executive Officer and Co-Founder of Roots Pharmaceutical. “OCU400 has the potential to change the outlook, and the lives, of patients living with retinitis pigmentosa. We look forward to working closely with Ocugen to build the diagnosis-to-treatment pathway that gene therapy requires across our markets, and to exploring further collaboration across Ocugen’s ophthalmology pipeline.”

Ocugen continues to advance OCU400 through its Phase 3 liMeliGhT clinical trial with a topline data readout expected in the first quarter of 2027, followed by global regulatory submissions, including a Biologics License Application in the U.S. and a Marketing Authorization Application in Europe.

About Ocugen, Inc.
Ocugen, Inc. is a pioneering biotechnology company developing gene therapies for blindness diseases. The Company’s breakthrough modifier gene therapy platform has the potential to address significant unmet medical needs across large patient populations through a gene-agnostic approach. Unlike traditional gene therapies and gene-editing technologies that target a single gene mutation, Ocugen’s modifier gene therapies are designed to address the underlying disease biology by restoring balance across multiple gene networks. The Company is currently advancing programs for inherited retinal diseases and other causes of blindness that affect millions worldwide, including retinitis pigmentosa, Stargardt disease, and geographic atrophy, an advanced form of dry age-related macular degeneration. Discover more at www.ocugen.com and follow the Company on LinkedIn and X.

About Roots Pharmaceutical Company
Founded in Kuwait in 2006, Roots Pharmaceutical is a fully integrated healthcare provider specializing in commercializing innovative therapies, medical devices, and an aesthetic line across the Middle East and North Africa. It is led by a team with over 25 years of pharmaceutical industry experience.

Roots Pharmaceuticals has established a direct commercial presence in the MENA region (Middle East and North Africa), mainly in GCC countries and key North African countries, with a therapeutic portfolio spanning neurology, hematology, oncology, rare diseases, dermatology, cardiovascular, medical devices and aesthetic line.

With 30+ global partners and a $300M+ product pipeline, Roots Pharmaceutical and its strategic partner Al-Dhow Group are committed to delivering meaningful healthcare impact across the MENA region through innovation, access and excellence. Its operations are ISO 9001:2015-certified and externally audited by PwC.

Cautionary Note on Forward-Looking Statements
This press release contains forward-looking statements within the meaning of The Private Securities Litigation Reform Act of 1995, including, but not limited to, statements regarding the anticipated benefits to Ocugen of the definitive license agreement and supply agreement with Roots Pharmaceutical Company, as well as statements regarding strategy, the potential amounts of milestone payments and royalty payments that may be received under the license agreement, business plans and objectives for Ocugen’s clinical programs, plans and timelines for the preclinical and clinical development of Ocugen’s product candidates, including the therapeutic potential, clinical benefits and safety thereof, expectations regarding timing, success and data announcements of current ongoing preclinical and clinical trials, including the timing of data readouts and marketing applications, the ability to initiate new clinical programs, statements regarding qualitative assessments of available data, potential benefits, expectations for ongoing clinical trials, anticipated regulatory filings and anticipated development timelines, statements regarding potential market size and commercial possibilities of Ocugen’s product candidates, which are subject to risks and uncertainties. Ocugen may, in some cases, use terms such as “predicts,” “believes,” “potential,” “proposed,” “continue,” “estimates,” “anticipates,” “expects,” “plans,” “intends,” “may,” “could,” “might,” “will,” “should,” or other words that convey uncertainty of future events or outcomes to identify these forward-looking statements. Such statements are subject to numerous important factors, risks, and uncertainties that may cause actual events or results to differ materially from Ocugen’s current expectations, including, but not limited to, the risks that the license agreement and supply agreement with Roots Pharmaceutical Company will not lead to the current anticipated benefits to Ocugen; that preliminary, interim and top-line clinical trial results may not be indicative of, and may differ from, final clinical data; that unfavorable new clinical trial data may emerge in ongoing clinical trials or through further analyses of existing clinical trial data; that earlier non-clinical and clinical data and testing may not be predictive of the results or success of later clinical trials; and that clinical trial data are subject to differing interpretations and assessments, including by regulatory authorities. These and other risks and uncertainties are more fully described in Ocugen’s filings with the Securities and Exchange Commission (SEC), including the risk factors described in the section entitled “Risk Factors” in the quarterly and annual reports that Ocugen files with the SEC. Any forward-looking statements that Ocugen makes in this press release speak only as of the date of this press release. Except as required by law, Ocugen assumes no obligation to update forward-looking statements contained in this press release whether as a result of new information, future events, or otherwise, after the date of this press release.

Contacts:

Investors:
Candice Masse, astr partners
[email protected]

Media:
Chris Clark, Ocugen
[email protected]

Release – Kodiak Extends Ketchan Mineralization by over 450 Metres with 0.41% CuEq over 122.5 Metres from Surface

Posted on by [email protected]

October 14, 2026 – Vancouver, British Columbia – Kodiak Copper Corp. (the “Company” or “Kodiak”) (TSX-V: KDK, OTCQX: KDKCF, Frankfurt: 5DD1) announces additional drill results from the summer 2026 drill program at its 100% owned MPD copper-gold porphyry project in southern British Columbia. Results received from seven holes totalling 1,583 metres drilled on the Ketchan deposit are reported herein (Figure 1).

Highlights

  • Drilling southeast of the Ketchan deposit expanded the mineralized envelope by a minimum of 450 metres beyond the deposit’s currently defined 1.4 kilometre strike extent. Notable drill results associated with the mineralized extension include: (Figures 2 and 3, Tables 1 and 2)
    • AG-26-034 intersected 0.31% Cu, 0.10 g/t Au and 1.70 g/t Ag (0.41% CuEq) over 122.5 metres from 5.5 metres to 128 metres
    • AG-26-021 intersected 0.12% Cu, 0.09 g/t Au and 0.76 g/t Ag (0.20% CuEq) over 202.5 metres from 39.5 metres to 242 metres
  • Hole AG-26-034 confirmed copper mineralization is associated with a large geophysical anomaly that extends one kilometer southeast from Ketchen. This3D-Induced Polarization (3D-IP) chargeability anomaly is untested southeast of AG-26-034. It is also coincident with anomalous soil and surface rock geochemistry. Figures 2 and 3
  • Additional results of interest include AG-26-015 which tested gaps in the central portion of the deposit. The hole intersected a gold rich zone with 0.19% Cu, 0.15 g/t Au and 0.58 g/t Ag (0.31% CuEq) over 207.3 metres from 22.7 metres to 230 metres. Figures 2 and 3, Tables 1 and 2
  • Kodiak expects these drill results to improve and expand the mineral resource at Ketchan, thereby continuing to grow the Mineral Resource Estimate (“MRE”) at MPD overall.
  • To date, 12,712 meters in 60 holes have been drilled in 2026 at the Ketchan, West and South deposits. A total of 16,500 metres of drilling is planned, with the goal of expanding a number of the deposits, as well as testing several prospective exploration targets that have potential for new discoveries. Drilling is expected to continue until late in the year.
  • All seven deposits in the current MRE are open to expansion and results from the 2026 drill program will contribute to an updated MRE, planned in Q1 2027.

“The recent drilling at the Ketchan deposit continues to deliver excellent results and suggests near-surface mineralization goes well beyond the current resource footprint.” said Claudia Tornquist, President & CEO of Kodiak Copper. “This demonstrates the scale of the mineralized system at Ketchan and could potentially result in a significant extension of the current deposit. With mineralization remaining open in this area, we see opportunities to further expand the deposit through continued step-out drilling.”

Figure 1: MPD Project – Location Map and Mineral Deposits

Picture1

Figure 2: Plan map showing the Ketchan deposit drilling to date. Bar graphs show downhole copper (green) and gold (red) values, and the background is the colour-contoured copper-in-soil data.

Picture2

Figure 3: Ketchan Deposit – Holes AG-26-007 to AG-26-008, AG-26-011, AG-26-015, AG-26-020 to AG-26-021 & AG-26-034 Long Section (Looking Northeast)

Picture3

Ketchan Deposit Drilling

The Ketchan deposit is located on the MPD Northwest claims and is a near-surface, alkalic porphyry copper-gold system defined by geophysics (aeromagnetics and induced polarization surveys), geology, rock sampling, and drilling. The current drill program, Kodiak’s first at Ketchan, is designed to target areas within, and adjacent to, the Mineral Resource Estimate (the “MRE”). As such, any mineralization intersected has the potential to expand the overall MRE.

Drill hole AG-26-034 was drilled towards the east from a pad located 450 metres southeast of the Ketchan deposit. A significant mineralized zone characterized by calc-potassic alteration was intersected from surface, between 5.5 metres and 128 metres, on the margin of a southeast trending 3D-IP chargeability anomaly. The 3D-IP anomaly extends for an additional 550 metres beyond this drill collar.

Drill hole AG-26-021 tested an intrusive monzonite porphyry associated with Ketchan and confirmed the body is mineralized throughout. The mineralization is characterized by bornite/chalcopyrite bearing veins.  When combined with historic hole K15-08, which returned 0.21 % Cu, 0.12 g/t Au and 0.97 g/t Ag (0.31% CuEq*) over 92 m from 15 metres to 107 metres, these three drill holes demonstrate a strong potential to expand the Ketchan MRE at least 450 meters to the southeast.

Drill hole AG-26-015 tested an area internal to the resource where the block model exhibited patchy mineralization. The hole intersected a gold rich zone over 200 metres and demonstrated continuity.

Drill hole AG-26-020 was drilled to the east of the MRE in an area with no known mineralization and intersected a zone of copper enrichment. Both drill holes are expected to enhance the resource.

Drill holes AG-26-007 and AG-26-011 targeted the area between the northwestern lobe and main lobe of the deposit. Both holes intersected lower grade mineralization, indicating the porphyry system is present. Additional drilling is required to further investigate this area.

Table 1: 2026 Ketchan Deposit Weighted Assay Intervals for Holes AG-26-007 to AG-26-008, AG-26-011, AG-26-015, AG-26-021 & AG-26-034 (see Figures 2 & 3).

HoleFromToInt(m)**Cu %Au g/tAg g/tCuEq*
AG-26-0345.5128122.50.310.101.700.41
AG-26-01522.7230207.30.190.150.580.31
AG-26-02139.5242202.50.120.090.760.20
AG-26-020115.515337.50.150.061.000.21
AG-26-007246336900.060.060.350.12
AG-26-01145.58640.50.030.020.270.05
AG-26-008No significant assays

*Copper equivalent grades (%CuEq) are for comparative purposes only to express the combined abundance of copper, gold, and silver. Metallurgical recovery is assumed as 82% for copper, 60% for gold and 54% for silver as determined by Kodiak metallurgical testing as stated in the Mineral Resource Estimate (see News Release June 25, 2025). Metal prices used in calculations are: US$4.75/lb copper, US3,500/oz gold, and US40/oz silver, using the formula: CuEq = Cu(%) + Au(g/t) x 0.7863 + Ag(g/t) x 0.0081

**Intervals are downhole drilled core intervals. Drilling data to date is insufficient to determine true width of mineralization. 

Table 2: 2026 Ketchan Deposit Drill Collar Information

Hole IDEasting
(UTM Z10)		Northing
(UTM Z10)		Elevation
(m)		Azimuth
(degrees)		Dip
(degrees)		EOH
(m)		Reported
AG-26-00767615155171781331170.3-503362026-10-14
AG-26-00867624455170021359180-752012026-10-14
AG-26-01167601855172241308270-601282026-10-14
AG-26-01567616455168161344274.8-602302026-10-14
AG-26-0206765225516827139650-752072026-10-14
AG-26-02167685255164871424330-502452026-10-14
AG-26-0346771055516255139590-502362026-10-14

Sampling, Laboratory Analyses and QA/QC Procedures

All core samples are delivered to accredited laboratory Activation Laboratories Ltd. (Actlabs) Kamloops, BC, for preparation and Fire Assay prior to being shipped to their Ancaster, Ontario Laboratory for Multi-element analysis. The maximum standard sample interval is 1.5 metres for HQ sized core and 3 metres for NQ sized core, with shorter intervals dictated by geological considerations.  The samples are analyzed for gold by fire assay fusion with an AA finish. If samples return gold values over 10ppm, samples are reanalysed by fire assay with gravimetric finish. Samples then undergo four acid digestion and ICP-OES and ICP-MS analysis for 48 elements. Samples that return copper values above 10,000 ppm are further analysed using a “near-total” digestion, ICP-OES package. Actlabs meets all requirements of International Standards ISO/IEC 17025:2015 and ISO 9001:2015 for analytical procedures. In addition to Actlabs quality assurance-quality control (QA/QC) protocols, Kodiak implements an internal QA/QC program that includes the insertion of sample blanks, duplicates, and certified reference materials, at a rate of one per ten samples.

Dave Skelton, P.Geo., Vice President Exploration and a Qualified Person as defined by National Instrument 43-101, has approved and verified the technical information in this news release. The company has not independently validated the historical component of the soil results or historic drill assays referenced herein; therefore, the reader is cautioned about the accuracy of the data. Copper-equivalent (CuEq) grades for historical drill results were calculated using the same formula, metal prices and metallurgical recovery assumptions applied to Kodiak’s drill results, as detailed in the notes to Table 1.

On behalf of the Board of Directors
Kodiak Copper Corp.

Claudia Tornquist
President & CEO

For further information contact:
Nancy Curry, VP Corporate Development
[email protected]
+1 (604) 646-8362